Answers are grounded in this paper and cite their sources.
, tepotinib is added to the list of targeted agents associated with pseudo-AKI. In this editorial we discuss the current literature regarding pseudo-AKI and true AKI associated with targeted agents, and subsequently propose a management strategy to monitor kidney function in patients treated with targeted agents.
No takes yet. Share an insight, caveat, or question.
Vanhoutte et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: